Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
ALK+ NSCLC
Anaplastic lymphoma kinase
Brigatinib
Molecular risk
Non-small cell lung cancer
Resistance mutations
Tyrosine kinase inhibitors (TKI)
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Jun 2021
28 Jun 2021
Historique:
received:
25
11
2020
accepted:
08
06
2021
entrez:
29
6
2021
pubmed:
30
6
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK In this exploratory prospective phase II clinical trial, newly diagnosed ALK Besides supporting therapeutic decisions for enrolled patients, the ABP trial primarily aims to deepen the understanding of the underlying biology and facilitate development of a framework for individualized management of ALK Clinicaltrials.gov , NCT04318938. Registered March 182,020, https://www.clinicaltrials.gov/ct2/show/NCT04318938 Eudra-CT, 2019-001828-36. Registered September 302,019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36.
Sections du résumé
BACKGROUND
BACKGROUND
Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK
METHODS/DESIGN
METHODS
In this exploratory prospective phase II clinical trial, newly diagnosed ALK
DISCUSSION
CONCLUSIONS
Besides supporting therapeutic decisions for enrolled patients, the ABP trial primarily aims to deepen the understanding of the underlying biology and facilitate development of a framework for individualized management of ALK
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov , NCT04318938. Registered March 182,020, https://www.clinicaltrials.gov/ct2/show/NCT04318938 Eudra-CT, 2019-001828-36. Registered September 302,019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36.
Identifiants
pubmed: 34182952
doi: 10.1186/s12885-021-08460-w
pii: 10.1186/s12885-021-08460-w
pmc: PMC8240323
doi:
Substances chimiques
Organophosphorus Compounds
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
brigatinib
HYW8DB273J
Banques de données
ClinicalTrials.gov
['NCT04318938']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
743Références
Clin Cancer Res. 2010 Mar 1;16(5):1561-71
pubmed: 20179225
Lancet Oncol. 2015 Jul;16(7):e342-51
pubmed: 26149886
J Cell Sci. 2020 May 11;133(9):
pubmed: 32184261
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Ann Oncol. 2017 Apr 1;28(4):791-797
pubmed: 28039177
J Clin Oncol. 2018 Aug 1;36(22):2251-2258
pubmed: 29768118
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
EBioMedicine. 2020 Dec;62:103103
pubmed: 33161228
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Cell Mol Life Sci. 2016 Mar;73(6):1209-24
pubmed: 26755435
J Thorac Dis. 2018 Jun;10(Suppl 17):S1989-S1991
pubmed: 30023099
J Clin Oncol. 2013 Mar 10;31(8):1105-11
pubmed: 23401436
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Cancer. 2019 Aug 1;145(3):649-661
pubmed: 30653256
Cancers (Basel). 2019 Jan 21;11(1):
pubmed: 30669647
J Clin Oncol. 2020 Nov 1;38(31):3592-3603
pubmed: 32780660
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Int J Cancer. 2019 Jan 1;144(1):190-199
pubmed: 30255938
Int J Cancer. 2018 Jun 15;142(12):2589-2598
pubmed: 29363116
Oncotarget. 2019 May 3;10(33):3093-3103
pubmed: 31139322
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Pathologe. 2019 May;40(3):276-280
pubmed: 31101971
Ann Oncol. 2018 Oct 1;29(10):2068-2075
pubmed: 30165392
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Clin Cancer Res. 2018 Jun 15;24(12):2758-2770
pubmed: 29599410
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Thorac Oncol. 2019 Jul;14(7):1233-1243
pubmed: 30902613
Biom J. 2006 Aug;48(4):714-29
pubmed: 16972724